Scarica l'app Stockscreener
423.55
0.87%
3.66
Dopo l'orario di chiusura:
423.55
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TMO Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$419.89
Aprire:
$428.47
Volume 24 ore:
2.49M
Relative Volume:
1.14
Capitalizzazione di mercato:
$160.15B
Reddito:
$42.90B
Utile/perdita netta:
$6.52B
Rapporto P/E:
24.84
EPS:
17.05
Flusso di cassa netto:
$6.72B
1 W Prestazione:
-0.16%
1M Prestazione:
-13.40%
6M Prestazione:
-24.08%
1 anno Prestazione:
-25.86%
Intervallo 1D:
$422.42
$431.44
Intervallo di 1 settimana:
$415.38
$432.85
Portata 52W:
$409.85
$627.88
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Nome
Thermo Fisher Scientific Inc
Settore
Industria
Telefono
(781) 622-1000
Indirizzo
168 THIRD AVENUE, WALTHAM, MA
Confronta TMO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
423.55 | 160.15B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
199.05 | 141.09B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
471.90 | 35.45B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
108.63 | 30.37B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
153.48 | 26.50B | 15.41B | 1.37B | 2.11B | 7.50 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-10 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2024-12-23 | Iniziato | Scotiabank | Sector Perform |
| 2024-10-14 | Iniziato | Redburn Atlantic | Buy |
| 2024-10-01 | Iniziato | Stephens | Overweight |
| 2024-08-28 | Iniziato | Wells Fargo | Overweight |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-03-18 | Ripresa | Citigroup | Neutral |
| 2024-01-24 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-01-08 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2023-12-18 | Iniziato | HSBC Securities | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-10-26 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-10-25 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-09-06 | Ripresa | Citigroup | Buy |
| 2023-07-19 | Iniziato | Raymond James | Outperform |
| 2023-07-19 | Reiterato | Robert W. Baird | Outperform |
| 2023-07-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2023-04-04 | Reiterato | Barclays | Overweight |
| 2022-12-14 | Iniziato | Deutsche Bank | Buy |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-10-27 | Downgrade | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Iniziato | Credit Suisse | Neutral |
| 2022-04-25 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2022-01-26 | Ripresa | Barclays | Overweight |
| 2021-10-20 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-08-05 | Ripresa | Credit Suisse | Outperform |
| 2021-07-16 | Iniziato | The Benchmark Company | Buy |
| 2021-03-18 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-03 | Iniziato | Barclays | Overweight |
| 2021-01-08 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-02 | Iniziato | Goldman | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Iniziato | Atlantic Equities | Overweight |
| 2020-09-14 | Iniziato | Morgan Stanley | Overweight |
| 2020-08-20 | Ripresa | JP Morgan | Overweight |
| 2020-07-15 | Aggiornamento | Cleveland Research | Neutral → Buy |
| 2020-07-07 | Reiterato | Needham | Buy |
| 2020-04-23 | Reiterato | Needham | Buy |
| 2020-01-31 | Reiterato | Needham | Buy |
| 2020-01-22 | Iniziato | Credit Suisse | Neutral |
| 2020-01-08 | Iniziato | Wells Fargo | Equal Weight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-07-25 | Reiterato | Needham | Buy |
| 2019-07-16 | Downgrade | Needham | Strong Buy → Buy |
| 2019-05-30 | Iniziato | Wolfe Research | Outperform |
| 2019-05-23 | Reiterato | Needham | Strong Buy |
| 2019-04-22 | Reiterato | Needham | Strong Buy |
| 2019-04-16 | Reiterato | BofA/Merrill | Buy |
Mostra tutto
Thermo Fisher Scientific Inc Borsa (TMO) Ultime notizie
Cell-Based Assays: The Future of Biomedical Breakthroughs - GlobeNewswire Inc.
RoosterBio Announces Collaboration with Thermo Fisher Scientific to Advance Cell & Exosome Therapy Manufacturing - PRWeb
THERMO FISHER SCIENTIFIC INC. SEC 10-Q Report - TradingView
Epigenetics Market Is Booming So Rapidly 2025-2032 -Illumina - openPR.com
Thermo Fisher Scientific Inc (TMO) Stock Analysis: A Closer Look at the 35.79% Potential Upside - DirectorsTalk Interviews
RoosterBio announces collaboration with Thermo Fisher to advance cell therapy manufacturing - BioSpectrum Asia
RoosterBio and Thermo Fisher Scientific Agree to Collaborate to Advance Cell and Exosome Therapy Manufacturing - Genetic Engineering and Biotechnology News
Lab Automation Market Set to Witness Significant Growth - openPR.com
Thermo Fisher commits $2bn to boost US operations - The Manufacturer
Thermo Fisher Scientific to cut jobs at Orlando location - WFTV
Thermo Fisher Scientific (NYSE:TMO) Collaborates With RoosterBio To Advance Cell Therapy Solutions - simplywall.st
Thermo Fisher Launches Improved Biological Safety Cabinet - Contract Pharma
Thermo Fisher reports Q1 growth, charts a steady course for 2025 - BioProcess International
RoosterBio Announces Collaboration with Thermo Fisher Scientific to Advance Cell and Exosome Therapy Manufacturing - WV News
Research Grade Proteins Market to Witness Massive Growth by 2032 - openPR.com
Thermo Fisher Scientific employs an enhanced platform technology - European Pharmaceutical Manufacturer
Cell Lysis Market Growth in Future Scope 2025-2032 | Thermo - openPR.com
Thermo Fisher Scientific Inc. (NYSE:TMO) Q1 2025 Earnings Call Transcript - MSN
RoosterBio, Thermo Fisher Partner to Advance Cell & Exosome Therapy Manufacturing - Contract Pharma
Thermo Fisher (TMO) Target Price Reduced by Argus | TMO Stock Ne - GuruFocus
Thermo Fisher To Buy Phadia For $3.5 Billion - CHEManager Online
Argus Adjusts Price Target on Thermo Fisher Scientific to $470 From $620 - marketscreener.com
Thermo Fisher accelerates development of biologic therapeutics - BioSpectrum Asia
Thermo Fisher Scientific Leverages Integrated Solutions to Accelerate the Development of Biologic Therapeutics - BioSpace
Pharmacogenomics Market Detailed In New Research Report 2025 | - openPR.com
Thermo Fisher Scientific to invest $2 billion to expand US operation - Indian Pharma Post
ENCell and Thermo Fisher Scientific discuss expanded collaboration in cell and gene therapy field - koreabiomed.com
Competent Cells Market Detailed in New Research Report By 2032 | - openPR.com
Thermo Fisher Scientific Announces $2B Investment to Expand U.S. Operations - Thomasnet
Is Thermo Fisher Scientific Gaining or Losing Market Support? - Benzinga
Thermo Fisher commits $2B to US manufacturing - MedTech Dive
Revvity joins peers Thermo Fisher, Danaher in tariff warning, maintains profit outlook - MSN
Thermo Fisher Streamlines Pre-Clinical Biologic Drug Development - Contract Pharma
Escherichia Coli Strain Market to Witness Massive Growth by 2032 - openPR.com
Thermo Fisher Scientific Inc (TMO) Stock Analysis: Exploring a 35.63% Potential Upside for Investors - DirectorsTalk Interviews
StockWatch: Tools Giants Foresee Revenue Impacts from Tariffs, Job Cuts - Genetic Engineering and Biotechnology News
Thermo Fisher Scientific Inc. (TMO): Among Billionaire Ken Fisher’s Healthcare Stock Picks with Massive Upside Potential - Insider Monkey
Press Release Distribution & PR Platform - ACCESS Newswire
Thermo Fisher Lowers 2025 Guidance as Trump Tariffs, Research Cuts Take Toll - Medical Device and Diagnostic industry
Scotiabank Adjusts Thermo Fisher (TMO) Price Target Amid Uncerta - GuruFocus
HSBC Adjusts Thermo Fisher Scientific Price Target to $590 From $670 - marketscreener.com
Thermo Fisher to invest $2 B over next 4 years to enhance innovation in US - BioSpectrum Asia
Cell Separation Market to Witness Remarkable Growth with Thermo - openPR.com
Gene Panel Market Set to Witness Significant Growth by 2025-2032 - openPR.com
Thermo Fisher to invest $2bn to strengthen US healthcare supply chain - World Pharmaceutical Frontiers
Thermo Fisher Scientific Reports First Quarter 2025 Results - ADVFN
Thermo Fisher updates 2025 revenue guidance to $43.3B-$44.2B amid macroeconomic challenges - MSN
Thermo Fisher counters tariffs with $2bn investment into US manufacturing - Pharmaceutical Technology
Thermo Fisher Doubles Down On US Manufacturing In $2B Expansion Plan - Benzinga
Thermo Fisher jumps on the US investment bandwagon with $2B in additional spending - Fierce Pharma
Thermo Fisher Scientific (NYSE:TMO) Completes US$3 Billion Buyback and Reports Rising Q1 Earnings - Yahoo Finance
Thermo Fisher Scientific Inc Azioni (TMO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):